1Juliano RL, l.ing V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J]. Biochem Biophys Acta, 1976,455( 1 ) :152.
2Borst P,Evers R,Ko I M ,et al. A family of drug transporters:the multidrug resistance-associated proteins[J]. J Natl Cancer Inst,2000,92 (6) :1295.
3Maliepaard M, van Gastelen MA,de Jong LA,et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line[J]. Cancer Res,1999,59(18) :4559.
4Seheper R J, Broxterman H J, Scheifer GL, et al. Overexpression of a M (r) 110,000 vesicular protein in non-P-glycoprotein-mediated Multidrug resistance[J]. Cancer Res, 1993,53 (7) :1475.
5Sandri MI, Hochhauser D, Ayton P, et al. Differential expression of the topoisomerase 11αand β genes in human breast cancers [J]. Br J Cancer, 1996,73 : 1518.
6Gruss H J, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas [J]. Blood, 1995,85(12) :3378.
7Saleem A, Ibrahim N, Patel M, et al. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. [J]. Cancer Res, 1997,57 ( 22 ) :5100.
8Watanabe T, Tsuge H, Oh-Hara T, et al. Comparative study on reversal efficacy of SDZ PSC 833,Cyclosporin A and verapamil on muhidrug resistance in vitro and in vivo[J]. Acta Oncol, 1995,34(2) :235.
9Lopes EC,Seolnik M, Alvarez E, et al, Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected muhidrug resistant routine leukemic celts[J]. Leuk Res,2001,25( 1 ) :85.
10Yague E, Higgins CF, Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther,2004,11 : 1170-1174.